Co Diagnostics Valuation
| C97 Stock | EUR 5.16 0.00 0.00% |
At this time, the firm appears to be overvalued. Co Diagnostics owns a latest Real Value of €4.95 per share. The recent price of the firm is €5.16. Our model approximates the value of Co Diagnostics from analyzing the firm fundamentals such as Return On Asset of 48.56, shares owned by institutions of 25.41 %, and Price To Earning of 5.79 X as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Co Diagnostics' price fluctuation is abnormally volatile at this time. Calculation of the real value of Co Diagnostics is based on 3 months time horizon. Increasing Co Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the C97 stock is determined by what a typical buyer is willing to pay for full or partial control of Co Diagnostics. Since Co Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of C97 Stock. However, Co Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.16 | Real 4.95 | Hype 5.16 |
The real value of C97 Stock, also known as its intrinsic value, is the underlying worth of Co Diagnostics Company, which is reflected in its stock price. It is based on Co Diagnostics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Co Diagnostics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Co Diagnostics helps investors to forecast how C97 stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Co Diagnostics more accurately as focusing exclusively on Co Diagnostics' fundamentals will not take into account other important factors: Co Diagnostics Total Value Analysis
Co Diagnostics is currently estimated to have takeover price of 202.65 M with market capitalization of 209.18 M, debt of 0, and cash on hands of 72.38 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Co Diagnostics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
202.65 M | 209.18 M | 0 | 72.38 M |
Co Diagnostics Investor Information
About 25.0% of the company shares are held by institutions such as insurance companies. The book value of Co Diagnostics was currently reported as 2.34. The company had not issued any dividends in recent years. Co Diagnostics had 30:1 split on the 15th of October 2025. Based on the key indicators related to Co Diagnostics' liquidity, profitability, solvency, and operating efficiency, Co Diagnostics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.Co Diagnostics Asset Utilization
One of the ways to look at asset utilization of C97 is to check how much profit was generated for every dollar of assets it reports. Co Diagnostics utilizes its current and long term assets almost 48.56 %, earning €0.49 for each euro of current and long term assets held by the firm. A positive asset utilization signifies that the company is slightly more productive with each euro of current and long term assets it owns. Strictly speaking, asset utilization of Co Diagnostics shows how productive it operates for each euro spent on its current and long term assets.Co Diagnostics Ownership Allocation
Co Diagnostics secures a total of 28.67 Million outstanding shares. Co Diagnostics owns 6.15 % of its outstanding shares held by insiders and 25.41 % owned by institutions. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.Co Diagnostics Profitability Analysis
The company reported the revenue of 96.35 M. Net Income was 46.22 M with profit before overhead, payroll, taxes, and interest of 57.96 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Co Diagnostics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Co Diagnostics and how it compares across the competition.
About Co Diagnostics Valuation
The stock valuation mechanism determines Co Diagnostics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Co Diagnostics. We calculate exposure to Co Diagnostics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Co Diagnostics's related companies.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection andor analysis of nucleic acid molecules. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. CO DIAGNOSTICS operates under Diagnostics Research classification in Germany and is traded on Frankfurt Stock Exchange. It employs people.
8 Steps to conduct Co Diagnostics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Co Diagnostics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Co Diagnostics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Co Diagnostics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Co Diagnostics' revenue streams: Identify Co Diagnostics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Co Diagnostics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Co Diagnostics' growth potential: Evaluate Co Diagnostics' management, business model, and growth potential.
- Determine Co Diagnostics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Co Diagnostics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for C97 Stock analysis
When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |